| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.5 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | CEP-701 | FIMM | pan-cancer | AAC | 0.088 | 0.5 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.033 | 0.5 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | 0.074 | 0.5 |